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Background & Aims: Comorbid or extraintestinal symp-
toms occur frequently with irritable bowel syndrome
and account for up to three fourths of excess health
care visits. This challenges the assumption that irrita-
ble bowel is a distinct disorder. The aims of this study
were to (1) assess comorbidity in 3 areas: gastroin-
testinal disorders, psychiatric disorders, and nongas-
trointestinal somatic disorders; and (2) evaluate ex-
planatory hypotheses. Methods: The scientific literature
since 1966 in all languages cited in Medline was sys-
tematically reviewed. Results: Comorbidity with other
functional gastrointestinal disorders is high and may be
caused by shared pathophysiological mechanisms such
as visceral hypersensitivity. Psychiatric disorders, espe-
cially major depression, anxiety, and somatoform dis-
orders, occur in up to 94%. The nongastrointestinal
nonpsychiatric disorders with the best-documented as-
sociation are fibromyalgia (median of 49% have IBS),
chronic fatigue syndrome (51%), temporomandibular
joint disorder (64%), and chronic pelvic pain (50%).
Conclusions: Multivariate statistical analyses suggest
that these are distinct disorders and not manifestations
of a common somatization disorder, but their strong
comorbidity suggests a common feature important to
their expression, which is most likely psychological.
Some models explain the comorbidity of irritable bowel
with other disorders by suggesting that each disorder is
the manifestation of varying combinations of interacting
physiological and psychological factors. An alternative
hypothesis is that the irritable bowel diagnosis is applied
to a heterogeneous group of patients, some of whom
have a predominantly psychological etiology, whereas
others have a predominantly biological etiology, and
that the presence of multiple comorbid disorders is a
marker for psychological influences on etiology.
Patients with irritable bowel syndrome (IBS) areabout twice as likely as comparison groups to be
diagnosed with a variety of other, nongastrointestinal
somatic disorders (Table 1). Herein, we discuss the most
common of these disorders to see what light they may
shed on the etiology of IBS. Before we do so, however, it
is important to appreciate the sheer number of these
comorbid symptoms and disorders, as well as their im-
pact on quality of life and health care costs:
1. Levy et al.1 reported that IBS patients make twice
as many health care visits per year as age-matched
controls, and as Figure 1 shows, 78% of the excess
health care visits are for nongastrointestinal so-
matic complaints. Drossman et al.2 also reported
that IBS patients make 3 times as many nongas-
trointestinal health care visits as control subjects.
2. Approximately 50% of IBS patients from primary
care and gastroenterology clinics have at least 1
comorbid somatic symptom.3 So common is the
reporting of nongastrointestinal comorbid com-
plaints in IBS patients that 1 group of investigators
has suggested that this reporting be used as a
diagnostic criterion for IBS.4
3. IBS patients also incur more than twice the health
care costs of non-IBS patients; 66% of these excess
costs are for nongastrointestinal indications.5
4. Patients with 1 or more comorbid somatic disor-
ders report more severe IBS symptoms,6,7 more
anxiety and depression,8 greater impairment in
quality of life,3,9 and more illness-related absentee-
ism3 than IBS patients without comorbid disor-
ders.
Investigating the origins of comorbidity in IBS is
important, because this may provide clues to reducing
Abbreviations used in this paper: ANS, autonomic nervous system;
CFS, chronic fatigue syndrome; CNS, central nervous system; IBS,
irritable bowel syndrome; TMJ, temporomandibular joint disorder.




Table 1. Prevalence of Comorbid Medical Conditions in IBS








79 IBS, 72 non-IBS
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of FM pts had IBS
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worse physical
functioning and quality







33.3% of the IBS pts had FMa Rome criteria, Bowel
disease severity
IBS  FM  IBS only
Jones et al.
200140
Questionnaire 3912 GI pts;
including 270 IBS
IBS had higher prevalence of several
self-reported disorders compared
to GI pt controls: HA 51% (OR:
1.46), BP 38% (OR: 1.41), PMS
18% (OR: 2.25), TMJ 16% (OR:
2.0), CFS 14% (OR: 2.0), DM 10%
(OR: 2.0)
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52% of CPP had IBS-type symptomsa
IBS symptoms associated with
symptom persistence at follow-up





Survey of IC pts 2405 pts with
interstitial cystitis













Lifetime history of IBS found in 92%
of CFS pts (OR, 5.1), 77% of FM
pts (OR, 4.3), 64% of TMD pts
(OR, 3.6), and 18% of CONT
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118 FM 52% of FM had IBS Criteria: Other
Hudson et al.
199231
Interview 33 female FM pts,
205 CONT
52% (OR, 26.0) lifetime prevalence
of IBS in FM









46 CFS, 92 physically
healthy CONT, 46
unselected controls
35% of CFS (OR: 3.5) had history of
IBS diagnosis














Questionnaire 127 CFS with 127
non-CFS healthy
co-twins
59% of CFS had IBS (OR, 6.6) Criteria: Pt. Report of
past diagnosis
April 2002 COMORBIDITY OF IRRITABLE BOWEL SYNDROME 1141
(continued on following page)
health care costs and treating IBS more effectively.
More fundamentally, however, the extent of co-
morbidity challenges the concept that IBS is a dis-
tinct diagnostic entity rather than a variant of a
psychiatric10,11 or a neuroendocrine12,13 disorder. In
this review, we begin by examining the disorders
and the symptoms that overlap with IBS at greater
than chance levels to see whether they share any
common pathophysiologic or psychological mecha-
nisms with IBS. We then review studies that examine
the comorbidity of IBS with multiple other symptoms or
disorders to test the hypothesis that IBS is not a distinct
diagnostic entity, but rather part of a general somato-
form disorder. Finally, we review hypotheses that at-
tempt to provide a unitary explanation for the comor-
bidity of IBS with other disorders, and we offer our own
view.
Methodologic Considerations
We searched the world medical literature indexed
in Medline from 1966 to the present for the following
terms: irritable bowel syndrome, IBS, functional bowel,
and colonic disorders–functional, in conjunction with
the terms comorbidity, comorbid disorder, psychiatric
illness, psychiatric disorder, mental disorder, somato-
form disorder, anxiety, anxiety disorder, depression, de-
pressive disorder, panic, panic disorder, somatization,
fibromyalgia, chronic fatigue syndrome, headache, tem-
poromandibular joint, TMJ, temporomandibular joint
dysfunction /disorder, TMD, pelvic pain, and interstitial
cystitis. Articles in any language were included if they
(1) examined the prevalence of IBS and at least 1 other
disorder (somatic, gastrointestinal, or psychiatric) and (2)
contained sufficient detail to evaluate how representative









IBS identified in 52.4% of
dyspareunia (OR, 1.9), 50% of
dysmenorrhea (OR, 1.8), 44.4% of
urinary symptom presenters (OR,














50 FM, 50 CONT 34% of FM pts had IBS (OR, 4.25) Criteria: Other
Sivri et al.
199624




Questionnaire 125 FM, 54
degenerative joint
disease, 46 CONT




Interview 77 CFS-only, 42 CFS
 depression, 26
depressed non-CFS






100 primary FM, 100
secondary FM, 100
arthritis controls
49% of primary FM, (OR, 5.4) 19%








469 female FM, 67
male FM, 36 male
CONT
IBS identified in 38.9% of female









60 FM 48% of FM met IBS criteria (OR, 2.5) Criteria: Other
Campbell et al.
198327
Questionnaire 22 FM, 22 CONT 50% of FM had IBS (OR, 10) Criteria: Other
aOdds ratio could not be calculated as there was no appropriate control group, or control group statistic was not reported.
bOdds ratio could not be calculated as none of the CONT subjects had IBS.
BHR, bronchial hyper-responsiveness; CFS, chronic fatigue syndrome; CONT, control subjects; CPP, chronic pelvic pain; DM, dysmenorrhea; FM,
fibromyalgia; HA, headache; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; PMS, premenstrual syndrome; TMJ, temporoman-
dibular joint disorder.
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Table 1 (continued). Prevalence of Comorbid Medical Conditions in IBS
the sample was and how diagnosis or classification was
made. We also examined the reference section of the
articles that we found to identify additional references,
and examined abstracts from Digestive Disease Week 2000.
Books were not included. Review articles were examined
for explanatory hypotheses and for additional references.
This was a systematic review, not a meta-analysis.
The comorbidity of IBS with other somatic disorders
has been the topic of several recent publications, but
systematic reviews have not been conducted. Azpiroz et
al.14 reported the consensus of an international working
team who concluded that “attempts to lump together
different functional syndromes lack any solid base, and
only constitute vain speculative exercises based precisely
on the absence of information regarding the different
conditions” (p. 71). Mayer et al.15 hypothesized that the
extraintestinal symptoms of IBS are caused by unique
characteristics of the afferent innervation of the viscera.
Most visceral afferents do not follow separate pathways to
the brain, but rather converge on dorsal horn cells in the
spinal cord that primarily receive afferent information
from somatic structures. Visceral afferent fibers from
each organ diverge, projecting to multiple spinal seg-
ments with resulting overlap. These 2 phenomena render
the sensations associated with visceral stimulation vague
or “fuzzy” and lead to the referral of visceral pain to other
somatic organs. Neither of these articles presented a
detailed review of the literature on comorbidity.
It must be acknowledged at the outset that a review of
this nature is hindered by the diversity of methods that
have been used in this research domain. Studies differ in
how they define IBS and other health conditions, and
study samples are often drawn from medical subspecialty
clinics. General conclusions can be made across studies,
because each study assesses cases and controls using the
same methodology, but absolute prevalence estimates
may not be comparable.
For the purposes of the review, we found it necessary
to depart from conventional terminology regarding co-
existing symptoms. Gastroenterologists have usually re-
ferred to comorbid somatic symptoms as “extraintesti-
nal” symptoms of IBS. This terminology implies that
IBS is the primary disorder and that comorbid somatic
disorders, such as fibromyalgia, are expressions of IBS.
We avoided this rather narrow perspective by using the
term “comorbid” somatic symptoms or disorders.
Specific Comorbid Somatic Conditions
Fibromyalgia. Fibromyalgia is a chronic condi-
tion of diffuse musculoskeletal pain associated with spe-
cific tender points on examination.12,16 It affects an esti-
mated 2% of the population.17 The association between
IBS and fibromyalgia has been studied more than any
other IBS comorbidity. Fibromyalgia occurs in approxi-
mately 32.5% (range, 28%–65%) of IBS patients7,18–21
(Table 1), and IBS occurs in an estimated 48% (range,
32%–77%) of patients with fibromyalgia.16,18,21–31
Chronic fatigue syndrome. Chronic fatigue syn-
drome (CFS) is defined as persistent or prolonged fatigue
for more than 6 months causing more than 15% impair-
ment, without medical or psychiatric conditions that can
account for the symptoms.32,33 The prevalence of CFS in
the general population has been estimated as 0.4%.34 Six
studies have examined the presence of IBS in patients
with chronic fatigue and reported a high degree of over-
lap, ranging from 35% to 92% (median, 51%).30,35–39
The only study to date to report on the prevalence of
CFS in IBS patients found that 14% reported a CFS
diagnosis.40
Chronic pelvic pain. Fourteen percent of women
report experiencing pelvic pain of more than 6 months at
some time.41 Five studies of patients reporting pelvic
pain have shown IBS to be a common comorbid condi-
tion, affecting 29%–79% (median, 49.9%) of women
with chronic pelvic pain.8,41–44 Walker et al.8 similarly
found that 35% of women with IBS reported chronic
pelvic pain (odds ratio, 2.54).
Temporomandibular joint disorder. Temporo-
mandibular joint disorder (TMJ) is characterized by oro-
facial pain, restricted jaw movement, and noise in the
jaw.45 It affects 21% of people,46 but only 5% seek
medical care.47 Aaron et al.30 reported that IBS was
present in 64% of 25 TMJ patients, and Jones et al.40
found a self-reported TMJ diagnosis in 16% of 270 IBS
patients.
Other disorders. Individual reports have sug-
gested significant comorbidity between IBS and a
number of other physical conditions, but these iso-
lated findings need to be replicated. IBS was reported
Figure 1. Annual outpatient visits by IBS patients and control sub-
jects. (Data from Levy et al.1)
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by 30.2% of 2045 survey respondents with interstitial
cystitis,48 compared with a prevalence of IBS in the
population of 9.4%.49 Jones et al.40 found that 38% of
IBS patients self-reported back pain, 18% reported
premenstrual syndrome, and 10% reported dysmenor-
rhea; all of these incidence rates are significantly
higher than those in other gastrointestinal patients.
Prior et al.50 found IBS to be common among gyne-
cologic referrals with dyspareunia (52.4%), dysmen-
orrhea (50%), urinary symptoms (44.4%), and non-
menstrual bleeding (40%). The overall IBS rate in this
sample of 798 gynecology patients was 37.3%, signif-
icantly higher than that seen in dermatology and ear,
nose, and throat clinic patients. Kennedy et al.51
identified IBS in 22.7% of individuals who had bron-
chial hyperresponsiveness.
Comorbid nongastrointestinal symptoms. Table
2 lists the nongastrointestinal symptoms (not diag-
noses) that are reported significantly more often by
IBS patients than by controls. Many of these are
musculoskeletal pain symptoms and fatigue symptoms
that are consistent with the comorbid diagnoses listed
in Table 1. However, Table 2 shows that urinary
symptoms consistent with detrusor hyperreflexia (i.e.,
increased frequency of micturition, urinary urgency,
nocturia) or bladder outlet dysfunction (i.e., urinary
hesitancy, incomplete bladder emptying) are also com-
mon in patients with IBS.
Do the Comorbid Disorders Share
Pathophysiologic Mechanisms With
Irritable Bowel Syndrome?
The 4 nongastrointestinal conditions just de-
scribed that are strongly associated with IBS share some
clinical features: They are all substantially more common
in women, may be triggered or exacerbated by stress, and
are associated with fatigue, sleep difficulties, anxiety, and
depression. Furthermore, these 4 disorders all have a high
degree of overlap with each other.30,52 It would seem
likely that disorders with so many similarities and excess
overlap would share a common etiology; however, the
evidence to support such a common etiology is uncon-
vincing. The pathophysiologic mechanisms believed to
account for the symptoms of IBS include:
1. visceral hypersensitivity53–55
2. autonomic nervous system dysregulation56
3. smooth muscle hyperreactivity, characterized by
exaggerated motility responses to a variety of pro-
vocative events54,57
4. abnormalities in the levels of neurotransmitters
such as serotonin or the receptors for these neuro-
transmitters58
5. sustained activation of the immune system after
infection,59–61 stress, or other psychological fac-
tors62,63
Table 2. Comorbid Nongastrointestinal Symptoms Significantly More Common in IBS Than Controls and Their Prevalence




















Headache 31 23.1 34 45
Back pain 61 27.6 44 81
Low back pain 37.1 88
Fatigue 63 36.3 47
Poor sleep 30
Decreased sex drive 13.4 26.9
Fever (subjective) 6
Shortness of breath 25
Wheezing
Muscle aches or soreness 36.3 29
Sensitivity to heat or cold 14
Dyspareunia 42 9.3




Incomplete bladder emptying 50
Pruritis 32
Bad breath/unpleasant taste in mouth 58 16.3 65
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6. sexual trauma history64–66
We first considered whether any of these pathophysi-
ologic mechanisms are common to one or more of the
nongastrointestinal somatic disorders that overlap with
IBS.
Visceral hyperalgesia. Pain sensitivity has been
most thoroughly investigated for fibromyalgia and IBS,
and the data do not support a common hypersensitivity
to pain as the explanation for comorbidity. Although two
thirds of IBS patients have lower visceral pain thresh-
olds,55 their somatic pain thresholds are normal67 or
higher than in normal controls.68 In contrast, patients
with fibromyalgia have decreased somatic pain thresholds
but normal visceral pain thresholds.69,70 It is only the
subgroup of patients who have both IBS and fibromyal-
gia who appear to have both visceral and somatic hyper-
sensitivity.69
Autonomic nervous system dysfunction. Tou-
gas56 speculated that autonomic dysfunction could be the
common pathophysiologic mechanism accounting for co-
morbid symptoms associated with IBS. More than a
dozen studies have assessed autonomic nervous system
(ANS) activity in IBS, but they have shown inconsistent
results, e.g., increased or decreased sympathetic activ-
ity71–75 and/or parasympathetic activity,76–79 or specific
ANS functional abnormalities only in particular symp-
tom subgroups.74,78,80 ANS function has also been stud-
ied in CFS and fibromyalgia, but here also results have
been inconsistent, with some studies showing no differ-
ence from healthy controls81–83 but others suggesting
elevated sympathetic activity and/or parasympathetic
withdrawal.84–89 In fibromyalgia, studies generally point
to elevated sympathetic and decreased parasympathetic
activity.90–92 Little is known about autonomic activity in
TMJ. In summary, autonomic abnormalities have been
described in 3 of these 4 common comorbid conditions,
but the findings are nonspecific (e.g., shift in autonomic
balance toward sympathetic predominance), and they
characterize a minority of the patients with these disor-
ders; thus, these findings do not suggest a specific phys-
iologic mechanism linking these disorders to IBS.
Hyperreactive smooth muscle. A specific type of
ANS dysfunction, smooth muscle hyperreactivity, is seen
in IBS54,93 and may also contribute to detrusor instability
and bronchospasm. However, no data are available on
such dysfunction in the other IBS comorbid disorders,
and smooth muscle dysfunction is unlikely to explain the
comorbidity of IBS with musculoskeletal disorders.
Immune dysfunction. Postinfectious IBS occurs
in approximately 25% of patients with a new onset of
gastroenteritis,59,60 and a similar etiologic mechanism
has been proposed for CFS.94 However, postinfectious
IBS is thought to occur only after gastrointestinal in-
flammatory reactions, whereas postinfectious CFS is
thought to be specific to systemic viral infections. It is
not clear how this hypothesis could account for the
overlap of IBS with CFS, or how it could account for the
comorbidity of IBS with other somatic disorders listed in
Table 1.
Serotonin hypothesis. Serotonin is involved pe-
ripherally in the regulation of motility and sensation in
the gut,95,96 whereas in the central nervous system (CNS)
it is involved in mood disorders.11 Antidepressants that
modify central serotonin levels and possibly also periph-
eral serotonin levels benefit patients with various chronic
pain syndromes97 including IBS.98 Similarities in re-
sponse to antidepressants are consistent with a common
pathophysiologic basis for IBS and these other disor-
ders,97 but this evidence is indirect. No data directly link
any of these disorders, except possibly IBS,58 to abnor-
malities in serotonin.
Stress reactivity and psychological symptoms.
For most of the disorders listed in Table 1, one third to
one half of patients are depressed or anxious or they
report that their symptoms are worsened by stress and/or
they have a psychiatric diagnosis.99 Moreover, there is
some indication that patients with 2 or more of these
disorders are more anxious and depressed than patients
with only a single diagnosis.8,18 This suggests that psy-
chological distress may be an etiologic factor common to
all of them. However, the psychological symptoms asso-
ciated with IBS are diverse, and the possible mechanisms
linking psychological symptoms to somatic complaints
are still speculative. Moreover, when anxiety and depres-
sion are entered into regression models to explain comor-
bidity of IBS with other somatic disorders, they do not
explain nearly all the variance.40,100,101
Sexual and physical abuse. A history of sexual
abuse, and to a lesser degree physical abuse, is more
common in IBS than in patients with other gastrointes-
tinal disorders.65–66,102,103 Sexual abuse is also more
common in TMJ,104–105 CFS,106 fibromyalgia,107–108
and chronic pelvic pain,108–109 and patients with a his-
tory of abuse score higher on scales measuring somatiza-
tion (i.e., the tendency to report multiple somatic symp-
toms).110–112 Thus, somatization may be the mediating
variable that places individuals with a history of abuse at
increased risk for developing both IBS and its most
frequently coexisting medical conditions. Consistent
with this speculation, Walker et al.108 found that pa-
tients who had both IBS and chronic pelvic pain had
significantly higher scores on somatization scales than
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those who had only IBS, and logistical regression analysis
demonstrated that the mean number of somatization
symptoms was the best predictor of which patients had
chronic pelvic pain in addition to IBS rather than IBS
alone.
Overlap With Other Functional
Gastrointestinal Disorders
The comorbidity of IBS with other functional
gastrointestinal disorders is even more striking than its
overlap with nongastrointestinal somatic conditions;
compare Table 3 with Table 1. However, this may have
a very different explanation, as follows:
1. It may occur because there is an overlap in the
symptoms used to diagnose these disorders; for
example, abdominal pain is common to IBS, func-
tional dyspepsia, noncardiac chest pain, and func-
tional anorectal pain.113
2. Visceral hyperalgesia is seen throughout the gas-
trointestinal tract in IBS,114 including the esoph-
agus,115 stomach,116 duodenum,117 ileum,118 and
colon.53 This appears to represent a common
pathophysiologic mechanism that also contributes
to noncardiac chest pain,119 functional dyspep-
sia,120 and possibly levator ani syndrome.121
3. Pangastrointestinal motility abnormalities may
also contribute to the overlap of functional gastro-
intestinal disorders. In IBS patients, motor abnor-
malities have been recorded in the stomach,122,123
proximal small intestine,124 and ileum,125 as well
as in the colon and rectum, and there are well-
described long reflex pathways that serve to coor-
dinate the transit of nutrients and the elimination
of toxins.126
So striking is the overlap among the functional gas-
trointestinal disorders that some have proposed that one
term, such as “irritable gut,” be used for all of them,127
and that drugs that are effective for 1 of these disorders
may be effective for others as well.128 However, factor
analysis studies continue to show that independent clus-
ters of symptoms correspond to most of the functional
gastrointestinal disorders129–133; this suggests that they
are distinct diagnostic entities despite a high degree of
overlap.
Overlap With Psychiatric Disorders
More than 20 studies have assessed the overlap
between IBS and psychiatric disorders in the last 3
decades and have found that 54%134 to 94%135,136 of IBS
patients meet criteria for at least 1 primary (axis I)
psychiatric disorder. Most studies show the prevalence of
psychiatric disorders in IBS to be 90% or better.135–140
Drawing conclusions about the prevalence of individual
psychiatric conditions based on a review of the literature
is fraught with problems, because the most common
diagnostic categories–anxiety, depression, and somatiza-
tion disorders–are known to overlap in medical popula-
tions.141,142 Empirical reports rarely take this factor into
account, tabulating prevalences individually for each di-
agnosis, and several of the studies in this area have not
assessed all 3 domains. Furthermore, many of these stud-
ies are limited by small sizes and self-selected groups of
patients recruited from gastroenterology clinics. Despite
these limitations, certain generalizations are possible:
1. Most IBS patients presenting in medical clin-
ics,135–140 and approximately 18% of people with
IBS seen in the community,143 have 1 or more
psychiatric disorders.
2. No single psychiatric disorder is uniquely associ-
ated with IBS. However, the psychiatric diagnoses
most commonly associated with IBS are major
depression, followed by generalized anxiety disor-
der.
3. Although much attention has been given to the
association between IBS and panic disorder, a rel-
atively modest 30% (range, 15%–41%)41,134–137,140
of IBS patients (modest by comparison with major
depression) meet diagnostic criteria for panic dis-
order. The association between panic disorder and
IBS may be overestimated, because the transitory
diarrhea and abdominal pain that normally occur
during panic attacks (extreme anxiety) may be
mistaken for the chronic intermittent symptoms of
IBS.
4. Somatization disorder is diagnosed in one fourth to
one third of IBS patients. However, the prevalence
of somatization disorder is probably underesti-
mated, because the standardized Diagnostic Inter-
view Schedule144 is known to underestimate the
prevalence of this disorder. Furthermore, somatiza-
tion disorder is only one of several psychiatric
diagnoses in the current DSM-IV-TR classification
of mental disorders145 that are collectively called
“somatoform disorders”; this list also includes such
problems as conversion disorder, pain disorder, and
hypochondriasis. Therefore, reported statistics on
the association of somatization disorder with IBS
represent only a portion of the psychiatric spec-
trum of somatization.
It is important to distinguish between somatization
disorder, which is a psychiatric diagnosis defined by
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explicit criteria,145 and the behavioral tendency to
report multiple somatic complaints, which is what
psychological tests of somatization measure. Somati-
zation trait can be defined as a predisposition to
experience and report many somatic symptoms that
have no pathophysiologic explanation, to misattribute
them to disease, and to seek medical attention for
them.146 These 2 concepts are related; somatization
disorder is diagnosed when the tendency to report
multiple somatic complaints is extreme, involving at
Table 3. Comorbidity of IBS With Other Gastrointestinal Disorders





Community survey 3169 respondents
including 546 with
IBS, 442 with BHR,
and 539 with GERD
46.5% of IBS pts had GERD, and 47% of
GERD pts had IBS (reported OR for
the association: 2.72).





Questionnaire 683 pts with IBS,
dyspepsia or both
37.1% of IBS had dyspepsia, 64.9% of










56% of IBS had dyspepsia (OR, 2.97)





Interview 127 functional GI
outpts, 163
gallstone disease
57% of IBS had dyspepsia and 47% of




Questionnaire 387 NCCP, 93 CCP,
81 CONT










23% of FD diagnosed with IBS (42%





Questionnaire 37 pts with
nonorganic upper
GI pain tracked
54% of FD pts reported IBS symptoms
initially, and 35% had IBS symptoms











Questionnaire 1540 GI pts; 22%
had FD and 15%
had IBS










IBS and 14% had
dyspepsia















IBS and 11.5% FD
57% of IBS were FD (OR, 5.0), and













11.6% had IBS and
13% had dyspepsia
Among respondents meeting IBS criteria,
21.1% had fecal incontinence (OR,
2.7), 34.3% had anorectal pain (OR,
3.0), 42.4% had dyschezia (OR, 3.1),
and 28.4 had FD (OR, 2.2). IBS was
found in 30.2% of fecal incontinence
pts (OR, 2.6), 33.1% of anorectal pain
pts (OR, 2.85), 38.9% of dyschezia










CCP, cardiac chest pain; FD, functional dyspepsia; GERD, gastroesophageal reflux disease; IBS, irritable bowel syndrome; NCCP, noncardiac
chest pain; OR, odds ratio.
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least 3 organ systems and beginning before age 30.145
However, less severe forms of this behavior are com-
mon and are known to have a profound influence on
health care utilization.142,147 The origin of somatiza-
tion trait is poorly understood, but it appears to be
related to modeling and reinforcement of illness be-
havior during childhood,1,148,149 stress or anxiety,150
and early sexual and physical trauma.110 –112
Is IBS a Distinct Entity or Part of a
Global Disorder?
This important question has been addressed by 3
types of studies: measurement of somatization, factor
analysis, and multivariate statistical analysis.
Measurement of Somatization
Talley et al.151 tested the hypothesis that IBS
and functional dyspepsia are due to the trait of som-
atization by administering the Psychosomatic Symp-
tom Checklist to 5 groups of patients: 82 IBS patients,
33 functional dyspepsia patients, 99 patients with
organic gastrointestinal disorders, 37 patients with
somatoform disorder who were recruited from a pain
clinic, and 143 healthy controls. The Psychosomatic
Symptom Checklist is a list of 17 diverse symptoms
that patients are asked to rate with respect to fre-
quency and intensity. The authors found that the
group of patients with somatoform disorder endorsed
significantly more items on the Psychosomatic Symp-
tom Checklist than the healthy controls; but the IBS
patients were not significantly different from controls.
They interpreted this as evidence that IBS and func-
tional dyspepsia are not due to somatization. However,
the results are ambiguous, because the IBS group was
intermediate between the somatoform group and the
healthy controls and not significantly different from
either.
Factor Analysis
Whitehead et al.129–131,152 and Talley et al.132,151
used exploratory factor analysis to show that gastrointes-
tinal symptoms aggregate together in discrete clusters,
providing support for the independence of IBS from
functional dyspepsia and other functional gastrointesti-
nal disorders. Robins and Kirmayer153 used confirmatory
factor analysis to show that IBS is associated with a
cluster of symptoms that are independent of fibromyal-
gia, CFS, anxiety, and depression. However, there is
moderately high overlap among the patients who endorse
these 5 distinct clusters of symptoms, which muddies the
waters somewhat.
Multivariate Statistical Analysis
Other investigators40,100,101 have used multiple
regression or analysis of covariance to determine whether
the comorbidity of IBS with nongastrointestinal symp-
toms is explained by psychological traits such as anxiety,
depression, and somatization. Statistically adjusting for
psychological symptoms reduced the differences between
IBS patients and controls in amount of comorbidity but
did not eliminate those differences.40,100,101
The 3 studies described in this section have limita-
tions and should be replicated. However, they suggest
that any adequate theory of what accounts for comorbid-
ity must take 3 characteristics into account:
1. The disorders listed in Table 1 are relatively inde-
pendent entities. They probably have independent
etiologic mechanisms, and they are not different
aspects of 1 disorder, such as somatization.
2. However, these disorders overlap much more fre-
quently than would be expected by chance. This
suggests that the patients who have these disorders
have something in common that is relevant to the
expression of all these disorders.
3. The common factor is most likely to be psycholog-
ical and to involve stress reactivity and/or a ten-
dency to selectively attend to somatic sensations
and to amplify their intensity and significance.
Hypotheses to Explain the
Comorbidity of IBS With Other
Somatic Disorders
Diagnostic Ambiguity
All of the disorders that are comorbid with IBS
are characterized by vague, sometimes overlapping
symptoms,154 and Mayer et al.15 suggested that there is
a physiologic basis for this vagueness: visceral afferents
converge with somatic afferents on the same dorsal horn
cells in the spinal cord, and the spinal segments to which
visceral afferents project are overlapping. Wessely et
al.155 further suggested that classification of these so-
matic symptoms into discrete diagnoses may be an arti-
fact of medical subspecialization: that is, confronted with
the same patient’s history, a gastroenterologist might
diagnose IBS, whereas a gynecologist might diagnose
chronic pelvic pain syndrome or dysmenorrhea, and a
rheumatologist might diagnose fibromyalgia. This hy-
pothesis could explain at least some of the comorbidity of
IBS with other somatic disorders (Table 1). However, the
symptoms associated with headache and TMJ are so
different from those of IBS and the afferent projections of
those target organs are so far removed that it seems
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unlikely this explanation could fit all cases. No data
directly support the diagnostic ambiguity hypothesis.
Affective Spectrum Disorder
Hudson and Pope11 carried out a systematic re-
view of the literature to identify all disorders that showed
a consistent response to 2 or more classes of antidepres-
sants. (The classes of antidepressants considered were
tricyclics, monoamine oxidase inhibitors, serotonin re-
uptake inhibitors, and atypical agents.) They reasoned
that disorders that respond to the same treatments prob-
ably share common etiologic elements. Their review
identified 8 such disorders: major depression, bulimia,
panic disorder, obsessive-compulsive disorder, attention
deficit disorder with hyperactivity, cataplexy, migraine,
and IBS. Subsequent experience suggests that other dis-
orders listed in Table 1 also respond to antidepressants
and are likely to meet Hudson and Pope’s criteria for
inclusion when more clinical trials have been published.
Further evidence for the affective-spectrum hypothesis
comes from the mammoth multinational study of de-
pression and somatization by Simon et al.142 Of 25,916
primary care patients from 15 primary care centers rep-
resenting 14 countries, 10% met criteria for major de-
pression, and 50% of these patients reported 3 or more
unexplained somatic symptoms. Unfortunately, the per-
centage of patients with 3 or more unexplained somatic
symptoms who did not have major depression was not
provided. Limitations of the affective spectrum hypoth-
esis include that not all patients with the disorders listed
in Table 1 are depressed, and not all of them respond
favorably to antidepressants. Moreover, antidepressants
down-regulate peripheral nociceptive pathways,156 and
this peripheral action may account for some of their
benefits.
Neuroendocrine-Immune Hypothesis
Investigators concerned primarily with under-
standing fibromyalgia and explaining its associations
with other disorders12,13 have proposed that there is a
common CNS abnormality in all of these disorders char-
acterized by a neuroendocrine-immune dysfunction, pos-
sibly related to deficient levels of serotonin or by exces-
sive amounts of CRH157 in the CNS. The emotional
motor system proposed by Mayer158 as a way of concep-
tualizing the multiple CNS and endocrine circuits in-
volved in the response of the gut to stress could also be
used to explain comorbidity of other disorders with IBS.
These are both conceptual models that have not yet been
directly supported by data.
Somatization
The trait of somatization is believed by some to
explain IBS and its association with other functional
somatic disorders. The somatization hypothesis allows
for some differentiation among different functional dis-
orders based on 3 mechanisms:
1. Childhood social learning contributes to symptom
reporting and the learning is relatively specific;
people tend to report the disorders and symptoms
that their parents modeled and reinforced during
childhood.1,148
2. There may be biologic differences between people
in the types of somatic sensations they experience,
and these differences can become amplified by psy-
chological processes.
3. Physical events (e.g., serendipitous gastroenteritis)
may direct the somatization tendency toward par-
ticular organ systems. For example, Gwee et al.159
found that individuals high in the traits of soma-
tization, anxiety, depression, and neuroticism were
the ones most likely to develop persistent IBS
symptoms 6 months after a confirmed episode of
gastroenteritis.
The limitations of the somatization hypothesis were
discussed earlier. There is evidence that IBS, CFS, and
fibromyalgia are independent disorders,153 and statisti-
cally controlling for psychological traits, such as soma-
tization and depression, does not explain away all of the
comorbidity of IBS with other somatic disorders.40,100,101
Multivariate Models
Various physiologic and psychological mecha-
nisms have been shown to be relevant to understanding
IBS, but no 1 of these mechanisms accounts for more
than two thirds of patients, and most account for less
than half. These etiologic mechanisms include visceral
hypersensitivity, ANS dysfunction, postinfectious IBS,
and psychosocial influences. There is evidence that these
different mechanisms may interact; for example, psycho-
logical stress predicts which patients with gastroenteritis
will develop postinfectious IBS,59 and abnormal gastro-
intestinal motility can interact with a low sensory thresh-
old to determine when patients experience abdominal
pain.160 This body of data has led to the biopsychosocial
model of IBS,161 which holds that (1) many factors or
influences contribute to symptom development, (2) no 1
of these factors is necessary to the development of the
disorder, and (3) these factors interact in different com-
binations. This biopsychosocial model may also apply to
the other disorders listed in Table 1.
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A different multivariate model has been proposed by
Naliboff et al.162 Like the biopsychosocial model, this
model emphasizes that there are many possible interac-
tions between physiologic and cognitive/psychological
processes that can give rise to IBS symptoms.
These multivariate models provide a way of under-
standing how the diverse disorders listed in Table 1 may
exist as separate entities and yet share common pathways,
which could lead to comorbidity. If all of these disorders
result from interactions between psychological and phys-
iologic factors, then some of these factors may be com-
mon to multiple disorders, whereas others are unique to
specific disorders. Examples of etiologic influences that
are common to many disorders include:
1. hyperalgesia occurring throughout the gastrointes-
tinal tract and contributing to both IBS and func-
tional dyspepsia
2. stress, which causes increased autonomic activity
and increased physiologic arousal
3. the psychological trait of somatization, which acts
like a nonspecific amplifier that magnifies the se-
verity and the significance of any somatic sensa-
tions present.
Examples of etiologic influences that are specific to
single disorders include genetically determined patterns
of physiologic reactivity (e.g., 1 child is a gut responder,
whereas another is innately a cardiovascular responder)
and childhood social learning in the form of selective
reinforcement and modeling of illness behavior by par-
ents, which may lead the child to become selectively
attentive to specific types of somatic sensations and to
interpret these sensations as symptoms of disease.
The principal limitation of these multivariate models
is that they are amorphous. They imply that there are no
etiologic factors necessary or sufficient to explain IBS or
any other disorder, and thus it is difficult to identify
testable mechanistic hypotheses and specific targets for
treatment.
Heterogeneity of Irritable Bowel Syndrome:
A Dual-Etiology Hypothesis
All of the hypotheses reviewed here that have
been proposed to explain the comorbidity of IBS with
other disorders assume that IBS is a homogeneous entity;
there may be different ways to get there, as proposed by
the biopsychosocial model, but all patients diagnosed
with IBS are presumed to have the same disease or
disorder. An alternative hypothesis is that a heteroge-
neous group of patients is currently labeled IBS, some
whose symptoms primarily have a biological basis and
others whose symptoms primarily have a psychological
basis, and comorbidity with other disorders and excessive
general somatic symptoms are markers for somatization
and identify the group with a predominantly psycholog-
ical IBS etiology, whereas patients with no comorbid
conditions and few general physical complaints are more
likely to have a biologic basis for IBS symptoms.
This dual-etiology hypothesis has several advantages.
It is more parsimonious and easier to understand than the
multivariate models, because it proposes only 2 etiologic
pathways to IBS rather than many. It has direct impli-
cations for the choice of treatment if patients can be
classified into these 2 categories (i.e., predominantly
physiologic or predominantly psychological). It gener-
ates some very specific predictions that are easily testable:
1. The relative prevalence of different comorbid disor-
ders in IBS patient samples will reflect the relative
prevalence of these disorders to each other in the
rest of the population, although the absolute prev-
alence of these disorders is greater in IBS. If con-
firmed, this would suggest that these disorders do
not share a common pathophysiologic mechanism
with IBS, but instead the excess incidence of these
disorders in IBS patients is caused by amplification
by a somatization process, such as selective atten-
tion and/or increased disease attribution.
2. The number of comorbid somatic disorders and
nongastrointestinal symptoms reported by IBS pa-
tients will be correlated with psychometric mea-
sures of depression, anxiety, stress, and/or parental
modeling of illness behavior, because comorbidity
is a consequence of, and thus a marker for, soma-
tization trait.
3. IBS patients with no comorbid somatic disorders
will be more likely to exhibit putative biological
markers for IBS, such as visceral hyperalgesia or
motility disturbances, in contrast to IBS patients
with multiple comorbid disorders, who would be
expected to lack biological markers for IBS.
By implying that there are only 2 etiologic mecha-
nisms for IBS (psychological and biological) that act
independently of each other, the dual-etiology hypothe-
sis is likely to be an oversimplification. There is good
evidence for the interaction of, for example, stress and
immune factors,59 and more than 1 biological mecha-
nism may be involved in the development of IBS. How-
ever, the dual-etiology hypothesis emphasizes that there
may be a subgroup of patients whose IBS symptoms
result from predominantly biological processes and another
subgroup whose IBS symptoms reflect predominantly psy-
chological etiologies; not all IBS patients are alike.
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If supported by research, the dual-etiology hypothesis
would help address some of the greatest challenges in
interpreting research on the nature and treatment of IBS.
First, it would help explain why all of the specific and
measurable characteristics of IBS patients, whether auto-
nomic dysfunction, motility disturbance, or visceral hy-
peralgesia, are absent in one half (or at least a substantial
proportion) of patients evaluated. Second, it would ex-
plain to some degree why most efforts to treat IBS,
whether pharmacologic or psychological, benefit only
about one half of the patients receiving the intervention.
Patients with a predominantly psychological basis for
their IBS symptoms are likely to respond to a different
class of treatments than patients with a predominantly
biological basis for their symptoms. If the 2 proposed
etiologic subgroups can be reliably identified by as sim-
ple a process as counting the number of comorbid so-
matic symptoms, then it may be possible to offer patients
more appropriate and effective treatment. There will
inevitably be patients who do not fit into these 2 (or
more) boxes and whose symptoms will seem to reflect the
interaction between psychological and physiologic pro-
cesses, but it is not clear how large this residual group
will be.
Study Limitations
The studies reviewed here have a number of lim-
itations, including the following:
1. Few of them are based on representative samples;
most come from subspecialty clinics, which are
affected by patient self-selection for treatment and
other forms of ascertainment bias.
2. The case definitions for IBS and the other disorders
of interest vary greatly across studies, and also have
changed over time.
3. Many of the studies involve very small samples.
4. The criteria for diagnosis vary from patient self-
report on questionnaires to clinical diagnosis by
unspecified symptom criteria or patient self-report,
to rather restrictive research criteria. Aaron and
Buchwald52 pointed out that as more restrictive
criteria are applied, the prevalence rates for the
disorders decline, as does the amount of overlap
that is seen.
5. The list of candidate comorbid symptoms or diag-
noses investigated varies from study to study; most
studies have focused on the overlap between only 2
specific disorders. These limitations make an accu-




Future work should assess large samples from
either the general population or general medical patients,
such as primary care patients; measure in the same
samples all the commonly known comorbid conditions;
and use well-defined clinical criteria for each of the
disorders assessed.
Dual-Etiology Hypothesis
This hypothesis has implications for the kinds of
experiments investigators might want to conduct on the
pathophysiology and treatment of IBS. It suggests that it
may be more productive to look for subgroups of patients
who fit a particular pathophysiologic mechanism (e.g.,
postinfectious etiology, hyperalgesia, or stress reaction)
or who respond to a specific treatment, rather than
assuming that 1 etiology and 1 treatment must charac-
terize all patients.
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